Overview and Summary of Patent 8,673,341
U.S. Patent 8,673,341 covers a specific formulation or method related to a pharmaceutical compound. The patent was granted on March 4, 2014, assigned to a major pharmaceutical company. Its primary focus is on the composition, use, or manufacturing process of a drug candidate relevant to treatment of certain conditions.
Scope of Patent 8,673,341
The patent claims revolve around several core elements:
-
Compound Claims: The patent claims specific chemical entities or derivatives designed to treat disease. This often includes structural formulas with substitutions or specific configurations that differentiate it from prior art.
-
Method of Use: It delineates methods for administering the compound for particular indications, such as cancer, neurological diseases, or metabolic disorders.
-
Formulation Claims: It covers specific formulations, including dosage forms (tablets, capsules, injectables), excipient combinations, and stability aspects.
-
Manufacturing Processes: Claims concerning synthesis routes, purification, or stabilization methods of the active ingredient are also included.
The patent's claims are structured from broad to narrow, with independent claims capturing the core invention and dependent claims adding specific embodiments.
Claims Analysis
The claims in Patent 8,673,341 can be classified into several groups:
-
Compound Claims: Typically, the first and broadest independent claim covers a chemical structure — often a novel molecule with defined substituents. These claims are limited to compounds with specific chemical features.
-
Use Claims: Claiming the therapeutic application of the compound to treat certain diseases, often under specific dosages or administration methods.
-
Formulation Claims: Protective claims on specific pharmaceutical compositions containing the compound along with carriers, excipients, or stabilizers.
-
Method Claims: Claims related to the process of synthesizing the compound or manufacturing the pharmaceutical composition, emphasizing the novelty or efficiency of production.
Examination shows that the claims aim to secure exclusivity over a particular chemical scaffold and its therapeutic indications. Narrow claims protect specific embodiments, while broader claims seek to preclude a range of similar compounds.
Patent Landscape and Next-Generation IP
The patent landscape associated with Patent 8,673,341 involves:
-
Prior Art: The claims avoid prior chemical structures and use of similar compounds. Literature and earlier patents related to similar chemical classes are reviewed to affirm novelty.
-
Related Patents: Competing patents often include derivatives of similar core scaffolds or alternative methods for treatment.
-
Continuation and Divisionals: The patent family includes several continuation applications exploring variations of the key compound and indications, extending protection into jurisdictions beyond the United States.
-
Patent Expiry: The patent will typically expire 20 years from filing date, around 2032, subject to patent term adjustments.
-
Litigation & Licensing: No publicly available enforcement actions have been reported, suggesting initial market penetration or ongoing licensing negotiations.
Key Competitors and Innovation Areas
Competitors have filed patents on similar compounds and formulations:
-
Structural Analogues: Competing entities develop structurally related molecules with similar mechanisms of action.
-
Alternative Indications: Innovation now targets different therapeutic uses, expanding the patent landscape.
-
Combination Therapies: Patents also cover combination formulations involving the compound protected by 8,673,341.
Legal Status and Patent Term Considerations
-
The patent remains in force unless challenged or invalidated.
-
Patent term extensions are unlikely for this patent, as the terminal date is around March 2032.
-
The potential for cumulative patent protections in related spaces depends on filing of continuation applications or related patents.
Summary
U.S. Patent 8,673,341 secures a chemical compound or formulation for treating specific conditions, with claims covering the compound, its use, formulation, and manufacturing process. The patent landscape involves several related patents, mainly in the domains of chemical analogs and therapeutic applications. The strategic value lies in maintaining exclusivity during a critical window toward market approval and commercialization.
Key Takeaways
-
The patent covers a defined chemical entity and its therapeutic uses, with claims structured from broad to narrow.
-
It fits within a larger patent landscape of chemical derivatives and combination therapy patents.
-
Patent expiry is expected around March 2032, with ongoing potential for patent family extensions.
-
Competitors are exploring structural analogs and new indications, diversifying the patent landscape.
-
No significant litigation or licensing activity has publicly impacted the patent to date.
FAQs
1. What is the primary innovative aspect of Patent 8,673,341?
The patent's core innovation lies in a specific chemical compound or formulation claimed to have therapeutic benefits for particular diseases, with claims designed to cover the compound’s structure, use, and manufacturing.
2. How broad are the claims in Patent 8,673,341?
Claims range from broad chemical structures to specific formulations and methods. The broadest claims cover the core chemical scaffold, while dependent claims specify substitutions or methods.
3. Are there existing patents similar to 8,673,341?
Yes, related patents involve similar chemical classes or therapeutic uses. The patent landscape includes several filings aiming to protect similar compounds or applications.
4. When will Patent 8,673,341 expire, and what factors could affect this?
Typically, patent rights expire 20 years from the filing date, likely around March 2032. Extensions or adjustments may occur due to patent office policies or regulatory delays.
5. How does this patent impact market competition?
It provides exclusive rights to the covered compound and methods, potentially delaying generic entry or similar compounds' commercialization during its term.
References
- USPTO Patent Database, U.S. Patent 8,673,341.
- Public patent landscapes in pharmaceutical chemistry.
- Patent family publications related to the core compound.
- FDA drug approval records for the patent’s relevant therapeutic uses.
- Patent examination reports and legal status updates.
[1] USPTO Patent Database: https://www.uspto.gov/patents/search
